CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Update

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the target of a significant drop in short interest during the month of August. As of August 31st, there was short interest totaling 2,193 shares, a drop of 82.6% from the August 15th total of 12,595 shares. Based on an average trading volume of 10,393 shares, the short-interest ratio is currently 0.2 days. Approximately 0.2% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

CNS Pharmaceuticals Stock Performance

Shares of CNSP traded up $0.09 during mid-day trading on Friday, hitting $5.84. 18,542 shares of the company’s stock were exchanged, compared to its average volume of 8,220. The company has a market cap of $8.53 million, a price-to-earnings ratio of -0.25 and a beta of 3.06. The stock’s 50-day moving average is $5.44 and its 200-day moving average is $4.36. CNS Pharmaceuticals has a fifty-two week low of $1.90 and a fifty-two week high of $10.59.

CNS Pharmaceuticals (NASDAQ:CNSP) last released its earnings results on Wednesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.14).

Institutional Investors Weigh In On CNS Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Armistice Capital LLC purchased a new position in shares of CNS Pharmaceuticals in the 2nd quarter valued at about $335,000. ADAR1 Capital Management LLC purchased a new position in CNS Pharmaceuticals in the second quarter worth approximately $335,000. Ikarian Capital LLC acquired a new position in CNS Pharmaceuticals during the 4th quarter worth approximately $241,000. Stonepine Capital Management LLC acquired a new position in CNS Pharmaceuticals during the 2nd quarter worth approximately $198,719. Finally, Boothbay Fund Management LLC purchased a new stake in shares of CNS Pharmaceuticals in the 4th quarter valued at approximately $71,000. Hedge funds and other institutional investors own 14.02% of the company’s stock.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.